Results 21 to 30 of about 99 (98)
Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang+7 more
wiley +1 more source
Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo+7 more
wiley +1 more source
Sequeira et al. reveal how the glucagon‐like peptide‐1 receptor agonist (GLP‐1‐RA) semaglutide restores cardiomyocyte function in rats subjected to a high‐fat/high‐fructose diet (HFD). Employing fluorescence‐ and patch‐clamp technology in isolated cardiac myocytes, they demonstrate that semaglutide reverses HFD‐induced activation of L‐type calcium ...
Vasco Sequeira+12 more
wiley +1 more source
Abstract Right ventricular failure (RVF) is a common complication following left ventricular assist device (LVAD) implantation and increases patient morbidity and mortality. Due to the complex and limited understanding of RVF pathophysiology, efforts to prognosticate RVF after LVAD have been challenging.
Abdul‐Fatawu Osman+11 more
wiley +1 more source
Abstract Background and objectives Initially described as a benign acute cardiomyopathy, Takotsubo syndrome has been linked to elevated mortality rates. Emerging evidence suggests that unresolved myocardial inflammation may contribute to this adverse prognosis.
Loïc Faucher+12 more
wiley +1 more source
Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad+9 more
wiley +1 more source
Percutaneous mechanical circulatory support for acute right heart failure: A practical approach
This is an overview of percutaneous mechanical circulatory support options for acute right heart failure, illustrating key clinical scenarios, device types, and principles of tailored device selection based on haemodynamics and underlying pathology. Abstract Acute right heart failure (RHF) represents a critical entity with significant morbidity and ...
Mario Gramegna+18 more
wiley +1 more source
Current and novel biomarkers in cardiogenic shock
A summary of current and novel biomarkers and their potential stages of release in cardiogenic shock. The diagram illustrates the proposed release of the biomarkers during the different stages of cardiogenic shock: progression from cardiac dysfunction/stress, through to inflammation and end‐organ dysfunction.
Victor Galusko+5 more
wiley +1 more source
Biocompatible and biodegradable liposomes were developed to encapsulate naringenin (N) and berberine (B), enhancing their stability and bioavailability. Their effects on thermogenesis and browning in 3T3‐L1 preadipocyte cells compared to their free forms were investigated.
Elif Didem Örs Demet+7 more
wiley +1 more source
Benzochalcogenodiazoles, Synthesis, and Applications in Medicinal Chemistry and Photomedicine
Benzochalcogenodiazoles (BXD) including benzoxadiazoles, benzothiadiazoles, and benzoselenadiazoles are initially mainly designed for optoelectronic materials as electron‐deficient cores. Nevertheless, they are now extending their application to biology.
Jean‐Elie Zheng+2 more
wiley +1 more source